Published in Cardiovascular Business Week, June 28th, 2005
In 2004, the group reported revenues of EUR721.3 million (US$765.1 million). A breakdown by business unit is as follows: 58%, or EUR416.1 million (US$504.8 million) for cardiac surgery; 24%, or EUR175.1 million, (US$212.4 million) for cardiac rhythm management; 3%, or EUR23.8 million, (US$28.9 million) for vascular therapy and new businesses; and 15%, or EUR105.7 million, (US$128.2 million) for renal care.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.